University of Bristol 4th May 2011

1
University of Bristol 4th May 2011
2
Agenda

• MRCs role within FP7
• Funding opportunities within FP7
• 2012 Health Work Programme
• Key points
• Topics by activity area

3
MRC and FP7

• MRC has four roles in FP7
• Participant
• NCP for the Health Theme Victoria Brewer
• Programme Management Committee (Health) Mark
  Palmer
• State Representative for Innovative Medicines
  Initiative Jill Jones

• MRC leads the PMC delegation at the invitation
  of the Department of Business Innovation and
  Skills (BIS)
• Alternative delegates are
• Department of Health (DH)
• Technology Strategy Board
• Expert group e.g. UKRO

• Joint lead between MRC and BIS

4
What is FP7

• Main mechanism used by the European Commission to
  fund research across Europe.
• Two main aims
• To strengthen the scientific and technological
  base of European industry.
• To encourage international competitiveness while
  promoting research that supports EU policies.
• How does the EC aim to achieve this?
• Pooling resources
• Integration of research
• Excellence in research
• Addressing Specific Needs

• Addressing Pan-European challenges
• Coordinating national and regional programmes
• Conducting comparative research at EU level
• Disseminating research result more widely

• Assembling critical mass
• Enabling big science
• Leverage private investment

• Orphan research

• Supporting research careers and mobility of
  research
• Creating world class centres of excellence
• EU level competition to increase quality and
  creativity

5
FP7 Budget

• Seven year funding programme with a budget of
  around 50.5 Billion

To date the UK has received 14 of the overall
funding awarded
6
Ideas European Research Council

• 7.5bn budget
• Managed through the European Research Council
  (ERC)
• Bottom up/investigator led research
• Research within your own team no international
  collaboration

• ERC Early grants
• Funding 1.5 M for up to 5 year
• 2-12 years post PhD at application
• UK has received 180 grants to date
• ERC-2010-StG call -79/427 went to UK HEI (19)

• ERC Advanced Grants
• Funding 2.5 M for up to 5 year
• exceptional research leader
• UK has received 172 grants to date
• ERC-2010-AdG call - 53/266 went to UK HEI (20)

7
People Marie Curie Actions

• 4.75bn budget
• Managed through Marie Curie Actions
• Research mobility and career development scheme
  inc
• coordination of PhD programmes
• Allows for European and International exchange
• Schemes for individuals or organisations
• To date 1.3 billion awarded
• UK share 300.8 million 23

• Individual
• Marie Curie Intra-European Fellowships for Career
  Development (IEF) -move from one EU or FP7
  associated country to another for a duration of
  1-2 years.
• Marie Curie International Incoming Fellowships
  (IIF) bring researchers based outside Europe
  into an EU Member State or country associated to
  FP7 for a duration of 1-2 years.

• Organisation
• Initial Training Networks (ITNs) aimed at
  initial training of researchers, first five years
  of researchers' careers. Projects will be based
  around a Joint Training Programme focussing on
  scientific and technological knowledge, as well
  as other complementary skills such as IPR,
  research management, entrepreneurship
• Co-funding of Regional, National and
  International Programmes (COFUND) - encourage
  existing or new regional or national programmes
  to open up and provide for trans-national
  mobility, as well as to reinforce international
  programmes.

8
Cooperation

• 32.4bn budget
• Top-down research
• EC sets the Research Agenda
• Proposals must be topic specific
• Multiple-disciplinary
• Collaborative research
• MUST be working with European Partners
• (or Associated Countries/ target specific
  countries)
• 3 is a magic number
• SICA 2x MS/AC 2x target region(s)

9
Who is eligible to participate?

• EU-27 Member States (MS)
• Austria, Belgium, Bulgaria , Cyprus, Czech
  Republic, Denmark, Estonia, Finland, France,
  Germany, Greece, Hungary, Italy, Ireland, Latvia,
  Lithuania, Luxemburg, Malta, Netherlands, Poland,
  Portugal, Romania, Slovakia, Slovenia, Spain,
  Sweden, UK
• Associated Countries (AC)
• Albania, Bosnia and Herzegovina , Croatia,
  Faroe Islands, FYR, Macedonia, Iceland,
  Israel, Liechtenstein, Montenegro, Norway,
  Serbia, Switzerland, Turkey
• except Euratom

10
Third countries ICPC
11
What organisation can participate?

• Participation is open to a wide range of
  organisations and individuals
• research groups at universities or research
  institutes
• small or medium-sized enterprises (SMEs)
• SME associations or groupings
• public or governmental administration (local,
  regional or national)
• organisations and researchers from third
  countries
• international organisations
• civil society organisations
• Need to register your organisation with the EC

12
Cooperation
Health 6.1bn
Food, Agriculture, Fisheries, Biotechnology 1.9bn
Information and Communication Technologies 9.1bn
Nano-sciences, nano-technologies, materials and new production technologies 3.5bn
Energy 2.4bn
Environment 1.9bn
Transport 4.2bn
Socio-economic sciences and the humanities 0.6bn
Space 1.4bn
Security 1.4bn
Obesity, allergies, zoonoses and systems biology
Medication information technologies, activities
on ageing, patient safety and virtual
physiological human being
Biomaterials for health application,
nanomedicines and nanotoxicology
Environment and Health
13
2012 Health Work Programme

• Research priorities
• Active Healthy Ageing
• Europe 2020 - Innovation Union ? The pilot
  European Innovation Partnership on active and
  healthy ageing
• 5 topics each looking to fund more than 1
  proposal, 4x 6m and 1x 12m
• Medical technologies
• Supporting the innovation" strategy and reduce
  the time to market
• 7 topics each looking to fund more than 1
  proposal, 6x 6m and 1x 3m
• Rare diseases
• Build critical mass for research on rare diseases
• Currently 4 topics and 1 HIP but likely to become
  7 topics
• Clinical Trials
• Continue on initiative started in 2011 work
  programme
• Improve the quality of clinical trial data in
  Europe
• 1x Active and Healthy ageing, 2x Rare diseases
  and 1xDiabetes (type 1)

14
2012 Health Work Programme

• Key features to look out for..
• Strong SME focus in the majority of call topics
• SME-targeted ? 30 budget
• SME-focus ? 15 budget
• Majority of call are 2 stage (exceptions CSA and
  ERA Net)
• Process
• Outline submission
• Invitation to second stage
• Full proposal submission
• Results

2011 WP Deadline 13th Oct 2010 20th Dec
2010 10th Feb 2011 end April/early May 2011
15
2012 Health Work Programme

• CLOSED AREAS
• BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL
  TECHNOLOGIES FOR HUMAN HEALTH
• 1.1 High-throughput research
• 1.3 Suitability, safety, efficacy of therapies
• 2. TRANSLATING RESEARCH FOR HUMAN HEALTH
• 2.2.1 Brain and brain-related diseases
• 2.3.1 Anti-microbial drug resistance
• 2.3.3 Potentially new and re-emerging epidemics
• 2.3.4 Neglected infectious diseases
• 2.4.1 Cancer
• 2.4.2 Cardiovascular diseases
• 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO
  EUROPEAN CITIZENS
• 3.1 Translating the results of clinical research
  outcome into clinical practice including better
  use of medicines, and appropriate use of
  behavioural and organisational interventions and
  new health therapies and technologies
• 3.3 Health promotion and prevention
• 4. OTHER ACTIONS ACROSS THE HEALTHTHEME

16
The Health Theme
1 Biotechnology, generic tools and medical
technologies for human health
2 Translating research for human health
3 Optimising the delivery of healthcare to
European citizens
4 Emerging policy needs/unforeseen needs
17
1.2 DETECTION, DIAGNOSIS AND MONITORING

• HEALTH.2012.1.2-1. Development of technologies
  with a view to patient group stratification for
  personalised medicine applications.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Research and development of technologies ?
  application of tailored medical intervention in
  specifically defined patient group
• Proof of principle highlighted
• Emphasis of data collection and analysis i.e.
  statistical tool quality control around this
• Active inclusion of end users (particular for
  proof of principle)

18
1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES

• Innovative Medicines Initiative
• Joint EC and EFPIA funding scheme 2 billion
• Research areas in
• Safety
• Efficacy
• Education training
• Knowledge management
• 4th call Estimated launched in June 2011
• Indicative topics
• Assessment of drug-induced toxicity in relevant
  organs surrogates for early drug failure
• Enhancing translation in neurological diseases
• European Medical Information Systems
• Stem Cells for drug development and toxicity
  screening
• Beyond high-throughput screening
• Disease heterogeneity/taxonomy of disease
• Genetic mapping of extreme phenotypes
• Combination therapy development

19
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS

• Focus Transplantation
• Rationale
• Clinical demand
• Continuity of successful FP6 projects
• Recent progress in other areas
• Policy developments i.e. DG SANCO

20
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS

• HEALTH.2012.1.4-1 Innovative approaches to solid
  organ transplantation.
• Key points
• SME-focused Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Improve the outcome, increase efficiency /or
  widen the scope of solid transplantation
• Clinical focus inc. Regulatory, safety
  immunological aspects
• Improved treatment ? improved personal targeting
  tolerance

21
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS

• HEALTH.2012.1.4-2 Medical technology for the
  transplantation sector and bioartificial organs
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Develop novel tools, techniques devices for use
  in transplantation and in bioartifical organs
• Include cells, tissues or organs
• Clinical/in-patient trial central to the
  proposal
• Cover safety efficacy assessment regulatory
  work

22
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS

• HEALTH.2012.1.4-3 Innovative strategies for
  translation of stem cell based therapies in
  regenerative medicine.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• EU and Australia Cooperation
• Australian Partners 50 work carried out in
  Australia
• Joint submission to EC and NHMRC
• Australian Partners apply to NHMRC ? request EU
  funds ? 6m max EC contribution to European Team
• Max NHMRC contribution 6m

23
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS

• HEALTH.2012.1.4-2 cont.
• Focus
• Characterisation
• Mechanisms of action and nature of host
  response(s)
• Quality control of product(s),
• Efficacy and safety in relevant preclinical
  models
• Bridging studies can be included
• 2 phase project ? 2nd stage dependent on
  regulatory approval
• 5 year review at Yr 3 ? Yrs 45 dependent on
  approval of joint regulatory filing
• funds divided equally between the 2 phases
• Outcome Therapeutic products clinical
  protocols developed with industrial partners

24
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND
INTERVENTIONS

• HEALTH.2012.1.4-4 Targeted nucleic acid delivery
  as an innovative therapeutic or prophylactic
  approach.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Immunotherapy, gene therapy or DNA vaccination,
  RNA interference
• Clinical testing carried out throughout of the
  life time of the project inc. regulatory work
• Preclinical work around safety, immunogenicity,
  toxicity and feasibility studies should have
  already been completed

25
The Health Theme
1 Biotechnology, generic tools and medical
technologies for human health
2 Translating research for human health
3 Optimising the delivery of healthcare to
European citizens
4 Emerging policy needs/unforeseen needs
26
2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES
LARGE-SCALE DATA GATHERING,SYSTEMS BIOLOGY

• 2.1.1 Large-scale data gathering
• HEALTH.2012.2.1.1-1 Clinical utility of -omics
  for better diagnosis and treatment of rare
  diseases.
• Key points
• WAS a High Impact Project going to broken down
  into individual Collaborative Project
• Focus
• New topics Still TBC
• Likely to cover
• -omics approaches and technologies for molecular
  characterisation for a chosen rare disease ? new
  diagnostics and treatment in clinical settings
• Utilisation of existing databases/biobanks
• Coordination and harmonisation of patient
  registries

27
2.1.1 Large-scale data gathering (cont.)

• HEALTH.2012.2.1.1-2 Validation of -omics-based
  biomarkers for diseases affecting the elderly.
• Key points
• SME-targeted Collaborative Project up to 12m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Clinical validation already identified -omics
  based biomarkers ? sensitivity, specificity and
  predictive power ? improved diagnosis, prognosis,
  patient stratification and/or treatment
  monitoring
• Inc. statistical models and quality control for
  data generated

28
2.1.1 Large-scale data gathering (cont.)

• HEALTH.2012.2.1.1-3 Statistical methods for
  collection and analysis of -omics data.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Improve or develop new statistical models / tools
  for analysis of omic based data
• Open to any omics based data e.g. genomics,
  proteomics etc or particular class of analysis
• Clinical trials excluded
• Must include appropriate training and
  dissemination activities

29
2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES
LARGE-SCALE DATA GATHERING,SYSTEMS BIOLOGY

• 2.1.2 Systems biology
• HEALTH.2012.2.1.2-1 Systems medicine SME-driven
  research applying systems biology approaches to
  address medical and clinical needs.
• Key points
• SME-targeted Collaborative Project up to 3m
• One or more proposals can be selected.
• Two-stage call
• Small to minimum consortium sizes
• Project duration up to 2 years
• No intermediate payments or reports

30
2.1.2 Systems biology (cont.)

• HEALTH.2012.2.1.2-1 cont.
• Focus
• Development, improvement and application of
  systems biology approaches to medical/clinical
  questions e.g.
• Re-design of clinical trials by shortening
  timescale and costs
• Development of combinatorial therapies and/or
  chronotherapies for complex diseases
• Development of combinatorial biomarkers
• Etc
• Establish proof-of-concept ? demonstrate the
  potential for exploitation
• Exploitation of results in clinical an/ or
  industrial sectors

31
2.1.2 Systems biology (cont.)

• HEALTH.2012.2.1.2-2 Systems medicine Applying
  systems biology approaches for understanding
  complex human diseases and their co-morbidities.
• Key points
• Collaborative Project up to 12m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Integrated multidisciplinary research inc.
  pre-clinical and clinical research ? clinicians,
  biologists computational scientists,
  mathematician etc
• Address a clear clinical need ? new avenues of
  understanding patho-physiology, diagnosis and
  treatment of complex diseases

32
2.1.2 Systems biology (cont.)

• HEALTH.2012.2.1.2-3 Preparing for the future
  research and innovation activities in systems
  medicine.
• Key points
• Coordination and Support Action (CAS) up to 3m
• Only one proposals can be selected.
• Two-stage call
• Focus
• Promote, support and coordinate research
  activities in systems biology across Europe
• Best practice, information and resources of
  successful methodological approaches.
• Multidisciplinary training requirements for the
  next generation
• Promote innovation activities ? technology
  transfer exploitation

33
2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES,
HUMAN DEVELOPMENT AND AGEING

• 2.2.2 Human development and ageing Primary
  focus
• Rationale
• Europe has highest proportion of older people in
  the world
• Grand challenge of understanding the ageing
  process
• More targeted geriatric medicines
• Innovation Union partnership Active and Healthy
  Ageing
• http//ec.europa.eu/research/innovation-union/inde
  x_en.cfm?sectionactive-healthy-ageing

34
2.2.2 Human development and ageing

• HEALTH.2012.2.2.2-1 Integrative systems biology
  and comparative genomics for studying human
  ageing and/or most common age-related diseases.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Interactions between genetics, epigenetic and
  environmental factors ? ageing phenotype in
  normal and disease conditions
• Computational approaches, comparative genomic
  studies of existing data and appropriate
  modelling
• Can include tools for diagnosis, prognosis and
  monitoring of therapies

35
2.2.2 Human development and ageing (cont.)

• HEALTH.2012.2.2.2.-2 Investigator-driven
  clinical trials for optimisation of management of
  elderly patients with multiple diseases.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Compare various treatment regimens in elderly
  population treated for multiple diseases
• Clinical trials looking at efficacy and adverse
  effects of multi treatment of common age related
  diseases

36
2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS
DISEASES TO CONFRONT MAJOR THREATS TO PUBLIC
HEALTH

• 2.3.0 Cross-cutting
• HEALTH.2012.2.3.0-1 Diagnostics for infectious
  diseases.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• No prescribed duration i.e. can be as short as
  1-2 years
• Focus
• Development and/or validation of diagnostic tests
  for major infectious diseases to meet clinical
  need
• Priority to diseases with unmet medical need
  i.e. no tests available improved testing ?
  better control and management

37
2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS
DISEASES TO CONFRONT MAJOR THREATS TO PUBLIC
HEALTH

• 2.3.2 HIV/AIDS, malaria and tuberculosis
• HEALTH.2012.2.3.2-1 Co-infection of HIV/AIDS,
  malaria, tuberculosis and/or hepatitis.
• Key points
• Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Basic, translation and/or clinical research
• prevention, therapeutic management and prognosis
  of co-infected patients
• Immunological mechanisms and response to
  co-infection
• Priority to co-morbidity of relevance to LMIC

38
2.3.2 HIV/AIDS, malaria and tuberculosis(cont.)

• HEALTH.2012.2.3.2-2 Co-morbidity between
  infectious and non-communicable diseases.
• Key points
• Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Basic, translation and/or clinical research
• prevention, therapeutic management and prognosis
  of patients infectious and non-communicable
  diseases
• Proposals should address
• Causative links between infectious and
  non-infectious diseases
• Combination of 3 major poverty related diseases
  (AIDS, malaria or TB) or any major poverty
  related diseases with non-infectious diseases

39
2.3.2 HIV/AIDS, malaria and tuberculosis(cont.)

• HEALTH.2012.2.3.2-3 Prevention and treatment for
  HIV/AIDS, malaria and tuberculosis.
• Key points
• SME-targeted collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• No prescribed duration i.e. can be as short as
  1-2 years
• Focus
• Basic or translation research addressing current
  gaps in
• Prevention and/or treatment of poverty related
  diseases (HIV/AIDS, malaria or TB)
• Proposal must inc
• Detailed plan for exploitation of end results
• Explore synergies with relevant EU funded
  initiatives e.g. European and Developing
  Countries Clinical Trial Partnership (EDCTP)

40
2.3.2 HIV/AIDS, malaria and tuberculosis(cont.)

• HEALTH.2012.2.3.2-4 Low-cost interventions for
  disease control in resource poor settings.
• Key points
• Collaborative Project up to 3m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Innovative ways to control neglected infectious
  diseases and/or malaria ? low-cost interventions
  immediate impact
• Novel applications of current tools and knowledge
  ? new cost-effective solutions
• Combinational therapy, treatment strategies,
  epidemiology, access to diagnostics and drugs,
  operational and implementation research
• Inclusion of partners from disease-endemic
  countries

41
2.4 TRANSLATIONAL RESEARCH IN OTHERMAJOR DISEASES

• 2.4.3 Diabetes and obesity
• HEALTH.2012.2.4.3-1 Innovative approach to
  manage diabetes.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Management of diabetes in pre-and/or clinical
  settings by validating therapeutic devices or
  biological therapies
• Attention to safety, bio-compatibility,
  interoperability and regulatory aspects ? fast
  and safe uptake of approaches/technologies

42
2.4.3 Diabetes and obesity (cont.)

• HEALTH.2012.2.4.3-2 Investigator-driven clinical
  trials for type 1 diabetes research.
• Key points
• Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Clinical Trial on type 1 diabetes with focus on
  paediatric population ? improve glycolic control
  and/or reduce diabetes complications
• Inform clinical management of type 1 diabetes
• Excludes pilot studies and systematic reviews

43
2.4 TRANSLATIONAL RESEARCH IN OTHERMAJOR DISEASES

• 2.4.4 Rare diseases ( lt 5/10,000)
• HEALTH.2012.2.4.4-1 Preclinical and/or clinical
  development of substances with a clear potential
  as orphan drugs.
• Key points
• Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• MUST be EU designated orphan medicinal products
• http//ec.europa.eu/health/documents/community-reg
  ister/html/orphreg.htm
• Preclinical studies in models and/or clinical
  studies
• Excludes cancer and diseases of the nervous
  system

44
2.4.4 Rare diseases (cont.)

• HEALTH.2012.2.4.4-2 Observational trials in rare
  diseases.
• Key points
• Collaborative Project up to 3m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Rare diseases with no orphan drug available
  treated off-label
• Improve clinical management of rare diseases ?
  evidence based clinical guidance
• Data collection and comparing outcomes of various
  treatment regimens
• Evaluation of effectiveness and adverse events
• Excludes cancer, infectious diseases and diseases
  of the nervous system

45
2.4.4 Rare diseases (cont.)

• HEALTH.2012.2.4.4-3 Best practice and knowledge
  sharing in the clinical management of rare
  diseases.
• Key points
• Coordination and Support Action (CAS) up to 2m
• Only one proposals can be selected.
• Two-stage call
• Focus
• Development of a networking platform supporting
  the collection of standardised validated data
  and exchange of information providing evidence of
  best clinical management of rare diseases
• Identify additional research needs
• Any group of rare diseases

46
2.4 TRANSLATIONAL RESEARCH IN OTHERMAJOR DISEASES

• 2.4.5 Other chronic diseases
• HEALTH.2012.2.4.5-1 Technological approaches to
  combating sensory impairments.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Preclinical and clinical testing of novel tools,
  devices or therapies' for overcoming sensory
  disability
• Prevention and treatment strategies,
  technological approaches, biological cell based
  therapies inc. Stem cells and development of
  bio-artificial organs

47
2.4.5 Other chronic diseases (cont.)

• HEALTH.2012.2.4.5-2 Biomarkers and diagnostics
  for chronic inflammatory diseases of the joints
  and/or digestive system.
• Key points
• SME-targeted Collaborative Project up to 6m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Development of improved/novel methodologies ?
  early diagnosis of chronic inflammatory diseases
• Indicative markers for inflammatory onset and
  development evaluation of intervention therapies

48
The Health Theme
1 Biotechnology, generic tools and medical
technologies for human health
2 Translating research for human health
3 Optimising the delivery of healthcare to
European citizens
4 Emerging policy needs/unforeseen needs
49
3.2 QUALITY, EFFICIENCY AND SOLIDARITYOF
HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH
SYSTEMS

• HEALTH.2012.3.2-1 Improving the organisation of
  health service delivery.
• Key points
• Collaborative Project up to 3m
• One or more proposals can be selected.
• Two-stage call
• 4 year duration
• Focus
• Best practice for European health care
  organisations around, structure, care processes
  and performance
• Areas to be addressed (either one or many)
• integration of patient care
• Patient centred care and involvement
• Skill mix and management of resources (only 1
  proposal)
• Transfer of knowledge into practice span 5
  years

50
3.2 QUALITY, EFFICIENCY AND SOLIDARITYOF
HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH
SYSTEMS

• HEALTH.2012.3.2-2 New methodologies for health
  technology assessment.
• Key points
• Collaborative Project up to 3m
• One or more proposals can be selected.
• Two-stage call
• Focus
• Develop new and/or improved methodologies for
  Health Technology Assessment (HTA)
• Areas of focus (either or both)
• Methodologies for addressing the complexity of
  interventions
• Methodologies to assess the efficacy and
  effectiveness of technologies
• Complement previously funded work i.e. EUnetHTA
  JA

51
3.4 INTERNATIONAL PUBLIC HEALTH HEALTH SYSTEMS

• HEALTH.2012.3.4-1 Health systems/services
  research in low and middle income countries.
• Key points
• SICA up to 6m
• 6x ICPC and min 2x EU/AC
• One or more proposals can be selected.
• Two-stage call
• 5 years in duration
• Focus
• Collection, analysis and translation of data into
  effective health service planning and policy
• Focus on (either)
• Methods to investigate country comparisons and
  scientific capacity
• Human resources for health
• Knowledge transfer
• Balanced partnership

52
The Health Theme
1 Biotechnology, generic tools and medical
technologies for human health
2 Translating research for human health
3 Optimising the delivery of healthcare to
European citizens
4 Emerging policy needs/unforeseen needs
53
4.1 COORDINATION AND SUPPORT ACTIONS ACROSS THE
THEME

• HEALTH.2012.4.1-1 Network to encourage knowledge
  transfer activity in FP-funded health research
  (especially in academic and governmental
  organisations). CSA 2m
• HEALTH.2012.4.1-2 Training actions linked to
  intellectual property rights management and
  knowledge transfer. CSA 2m
• HEALTH.2012.4.1-3 Support for Presidency events
  Organisation of supporting actions and events
  related to the Presidency of the European Union.
  CSA 100,000
• HEALTH.2012.4.1-4 Support for the international
  rare disease research. CSA 100,000
• HEALTH.2012.4.1-5 Communicating the benefits of
  European research to the general public. CSA
  100,000

54
(No Transcript)
55
Contacts

• NCP Health (Academia) Victoria Brewer
  victoria.brewer_at_headoffice.mrc.ac.uk
• 020 7395 2205
• NCP Health (Industry) Graham Hughes
• graham.hughes_at_betatechnology.co.uk
• 01302 322633
• NCP ERC Marie Curie UK Research Office
  ukro_at_bbsrc.ac.uk
• 00 32 2 230 1535 /5275

56
Useful websites

• EC website
• http//cordis.europa.eu/fp7/home_en.html
• Connect FP7
• https//ktn.innovateuk.org/web/fp7uk
• UKRO website
• http//www.ukro.ac.uk/
• MRC website International funding opportunties
• http//www.mrc.ac.uk/Fundingopportunities/Interna
  tionalopportunities/index.htm

57
Useful websites

• Europe 2020 Strategy
• http//ec.europa.eu/resource-efficient-europe/
• Innovation Union http//ec.europa.eu/research/inno
  vation-union/index_en.cfm?pgintro
• Active and Healthy Ageing http//ec.europa.eu/rese
  arch/innovation-union/index_en.cfm?sectionactive-
  healthy-ageing
• EDCTP
• http//www.edctp.org/

58
Any questions?